Stockscreener 앱 받기
7.46%
시장 영업 전:
전일 마감가:
$179.14
열려 있는:
$185.12
하루 거래량:
11.52M
Relative Volume:
2.22
시가총액:
$135.32B
수익:
$24.78B
순이익/손실:
$3.68B
주가수익비율:
37.20
EPS:
5.1743
순현금흐름:
$5.29B
1주 성능:
-6.10%
1개월 성능:
+7.56%
6개월 성능:
-18.09%
1년 성능:
-2.72%
1일 변동 폭
$183.87
$192.89
1주일 범위
$165.75
$206.59
52주 변동 폭
$160.93
$242.80
다나허 Stock (DHR) Company Profile
명칭
Danaher Corp
전화
(202) 828-0850
주소
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, IDXX, A, NTRA
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
192.50 | 135.32B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
572.32 | 212.69B | 45.20B | 6.87B | 6.75B | 18.19 |
IDXX
Idexx Laboratories Inc
|
539.37 | 42.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
139.74 | 39.47B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
264.69 | 37.91B | 2.50B | -226.32M | 71.51M | -1.6412 |
다나허 Stock (DHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Goldman | Buy |
| 2025-12-02 | 개시 | Morgan Stanley | Overweight |
| 2025-10-08 | 다운그레이드 | Rothschild & Co Redburn | Buy → Neutral |
| 2025-07-11 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-04-10 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-03-21 | 업그레이드 | Goldman | Neutral → Buy |
| 2025-03-14 | 업그레이드 | Stifel | Hold → Buy |
| 2025-02-03 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-12-23 | 개시 | Scotiabank | Sector Perform |
| 2024-12-19 | 개시 | Guggenheim | Buy |
| 2024-12-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-31 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-10-01 | 개시 | Stephens | Overweight |
| 2024-08-28 | 개시 | Wells Fargo | Equal Weight |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-17 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-01-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-12-18 | 개시 | HSBC Securities | Hold |
| 2023-12-13 | 재개 | Wolfe Research | Peer Perform |
| 2023-12-07 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-19 | 개시 | Raymond James | Outperform |
| 2023-05-01 | 개시 | SVB Securities | Outperform |
| 2023-04-26 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-18 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-01-05 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-10-24 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-08-17 | 재개 | Bernstein | Outperform |
| 2022-07-20 | 개시 | UBS | Buy |
| 2022-06-01 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-01-11 | 개시 | Bernstein | Outperform |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-09-10 | 재확인 | BofA Securities | Buy |
| 2021-08-05 | 재개 | Credit Suisse | Outperform |
| 2021-07-23 | 재확인 | Goldman | Buy |
| 2021-07-16 | 개시 | The Benchmark Company | Buy |
| 2021-04-07 | 재개 | Robert W. Baird | Outperform |
| 2021-03-03 | 재개 | Barclays | Overweight |
| 2020-12-02 | 개시 | Goldman | Buy |
| 2020-11-25 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-06-16 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-04-02 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2020-03-26 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-02-03 | 재확인 | Needham | Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-11-15 | 재개 | Stifel | Hold |
| 2019-10-28 | 재확인 | Needham | Buy |
| 2019-10-14 | 재개 | Credit Suisse | Outperform |
| 2019-07-19 | 재확인 | Needham | Buy |
| 2019-06-11 | 개시 | Piper Jaffray | Neutral |
| 2019-05-30 | 개시 | Wolfe Research | Outperform |
| 2019-04-17 | 재확인 | Needham | Buy |
| 2019-02-28 | 재확인 | Needham | Buy |
| 2019-02-25 | 업그레이드 | Janney | Neutral → Buy |
| 2019-01-03 | 개시 | Needham | Buy |
| 2018-04-20 | 재확인 | Stifel | Buy |
모두보기
다나허 주식(DHR)의 최신 뉴스
Danaher Corp (DHR) Stock Up 7.5% and Still Undervalued -- GF Sco - GuruFocus
Danaher Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Danaher Corp Stock (DHR) Moved Up by 6.78% on Jul 23: What Signal Does It Send? - TradingKey
Beckman Coulter Diagnostics Launches Fully Automated Urinalysis System to Meet Rising Testing Volumes - Financial Times
DHR Maintains Buy Rating -- Price Target Lowered to $236 by TD C - GuruFocus
U.S. RESEARCH ROUNDUP-Danaher, GM, MSCI - Bitget
TD Cowen cuts Danaher stock price target on bioproduction timing By Investing.com - Investing.com South Africa
Danaher stock trades steady as investors weigh life sciences growth and recent margin trends - Ad-hoc-news.de
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Sahm
Danaher Corporation (DHR) technical analysisDanaher (NYSE:DHR) - Benzinga
DHR Maintained by Wells Fargo -- Price Target Lowered to $195 - GuruFocus
Stifel cuts Danaher stock price target on bioprocess weakness By Investing.com - Investing.com South Africa
Stifel cuts Danaher stock price target on bioprocess weakness - Investing.com UK
DHR Maintained by Guggenheim -- Price Target Lowered to $200 - GuruFocus
Danaher Posts Mixed Q2 Results, Outlook for 2027 and Beyond Strengthened, RBC Says - marketscreener.com
Don't quit on Danaher stock after horrific earnings reaction - MSN
TD Cowen cuts Danaher stock price target on bioproduction timing - Investing.com
Can Danaher (DHR) Climb 32.39% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Danaher Q2 2026 Deep Dive: EPS Beats by 4.9%, Revenue Up 6% - AlphaStreet
Cepheid to Unveil Third-Generation GeneXpert® System at ADLM 2026, Advancing Molecular Diagnostic Capabilities - PR Newswire
Deutsche Bank Adjusts Danaher Price Target to $240 From $250, Maintains Buy Rating - marketscreener.com
Guggenheim cuts Danaher stock price target to $200 on bioprocessing concerns - Investing.com Canada
Danaher Stock Fell 11% After Earnings. Here’s What Could Drive It in 2026 - TIKR.com
Danaher (NYSE:DHR) Returns To Value Stock Focus After Results Update - Kalkine Media
Danaher revenue up 5.5% to USD 6.3B in Q2 2026 - Medical Buyer
Danaher Shares Drop 11% After Biotech Division Growth Falls Short of Expectations, Forcing Valuation Adjustment - TechStock²
Danaher (DHR) Experiences Notable Decline Amid Market Fluctuatio - GuruFocus
Leerink Partners Adjusts Price Target on Danaher to $240 From $270, Maintains Outperform Rating - Moomoo
Danaher’s Q2 Earnings Call Shows Life Sciences at Its Best Quarter in Years - TIKR.com
Wells Fargo Adjusts Price Target on Danaher to $195 From $212, Maintains Equalweight Rating - marketscreener.com
Danaher (DHR) Experiences Significant Decline - GuruFocus
Danaher Shares Slide 11% as Valuation Drops Following Biotech Growth Miss - TechStock²
Guggenheim Adjusts Price Target on Danaher to $200 From $235, Maintains Buy Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on Danaher to $210 From $230, Maintains Buy Rating - marketscreener.com
Danaher (DHR) Reports Q3 Revenue Growth of 2%-3% Year-over-Year - GuruFocus
Don’t Quit on Danaher Stock After Horrific Earnings Reaction - Barron's
Key facts: Danaher strong cash; trims 2026 outlook; bio orders, $100M deferred - TradingView
Geopolitical Conflicts and Energy Shocks Cloud Danaher’s 2026 Financial Outlook - TipRanks
DHR SWOT Analysis: Strong Financials Amidst Competitive Challenges Revealed in 10-Q Filing - GuruFocus
Danaher (DHR) Q2 2026 Earnings Call Transcript - The Motley Fool
Danaher (DHR) Reports Strong Q2 Earnings, Stock Drops Due to Ord - GuruFocus
Danaher Earnings Call Signals Growing Core Momentum - TipRanks
Danaher (DHR) Reports Strong Q2 2026 Results and Raises EPS Guid - GuruFocus
Danaher Corporation’s Stock Price Plummets to $179.01, Registering a Sharp 10.99% Drop - Smartkarma
Is Danaher Corp (DHR) a Bargain After 11.0% Drop? GF Value Says Undervalued - GuruFocus
The 'Surprisingly Soft' Unit That Caused Danaher To Plummet - Investor's Business Daily
Danaher (DHR) Reports Strong Q2 Earnings, Raises Full-Year Guida - GuruFocus
Danaher Posts Strong Q2 Results Driven By Life Sciences And Masimo Acquisition - insights.citeline.com
Danaher Corporation Provides Revenue Guidance for the Third Quarter 2026 - marketscreener.com
Why Danaher (DHR) Shares Are Falling Today - Yahoo Finance
Danaher (NYSE:DHR) in Focus on A Heavy Earnings Day For Healthcare - Kalkine Media
다나허 (DHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
8.71%
1.03%
자본화:
|
볼륨(24시간):